Lucerastat
Fabry Disease
Phase 3Development status post-prioritization
Key Facts
About Idorsia
Idorsia's mission is to discover, develop, and commercialize innovative medicines, building on a legacy of scientific excellence from its Actelion origins. Its key achievement is the global commercialization of QUVIVIQ (daridorexant), a dual orexin receptor antagonist for insomnia, alongside the recent approval of TRYVIO/JERAYGO (aprocitentan) for resistant hypertension. The company's strategy is centered on unlocking the full value of its commercial assets, expanding strategic partnerships, advancing a prioritized pipeline, and maintaining financial discipline, all supported by a highly skilled team of approximately 500 employees.
View full company profileOther Fabry Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| Corrector Program | Octant Biotech | Hit to Lead |
| GMAC for Fabry Disease | CellGenTech | Preclinical |
| JR-171 (lepunafusp alfa) | JCR Pharmaceuticals | Phase 3 |
| Undisclosed Gene Therapy | uniQure | Preclinical |
| PRX–115 (pegunigalsidase alfa) | Protalix BioTherapeutics | Submitted |
| Isaralgagene civaparvovec (ST-920) | Sangamo Therapeutics | Phase 1/2 |